Brian Gallagher, Jr has left SR One after eight years as a partner, setting up a Boston office on the way, to join Abingworth.

Brian Gallagher, Jr has departed from a partner position at SR One, the corporate venture capital arm of pharmaceutical firm GlaxoSmithKline, to take the same position at investment group Abingworth.

Gallagher joined SR One in 2010 after two years as director and then senior director of corporate development for Sirtris Pharmaceuticals, a biotech developer acquired by GlaxoSmithKline for $720m.

During his time at SR One, Gallagher helped set up the unit’s Boston office, and will work in the Boston office…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.